Leading sponsor: 100% Optical

Since launching in 2014, 100% Optical has quickly established itself as the largest optical event in the UK, attracting 8,936 international visitors and more than 200 exhibitors at our 2018 edition of the show.

Organised in partnership with the Association of Optometrists (AOP), the annual show provides a platform for professionals to:

  • Source the latest eyewear, technology and solutions for their businesses
  • Gain invaluable CET points as part of our world-leading education programme
  • Network with fellow industry peers through one-to-one meetings and parties

The next 100% Optical will take place on 12-14 January 2019 at London’s ExCel.

100% Optical event director, Nathan Garnett said:

We’re delighted to collaborate with Julian Jackson and VisionBridge to help raise awareness of sight loss and the work they do to promote eye research. Our goal has always been to support and enhance the optical sector and this is the perfect cause for us to champion this year. 

100% Optical is much more than just an industry event and has always strived to provide a thought leadership platform and influential “voice” for eye health innovation.

Julian has supported 100% Optical since the beginning and it’s now time for us to help him spread the word about his next big campaign, the Big Blind Walk. We’ll even be donning our walking shoes to join in next May!

This year was our fifth anniversary, and it really exceeded all expectations. We had double digit growth on visitor figures, which of course contributes to having a great impact on the awareness of VisionBridge and boost support for the Big Blind Walk.

100% Optical works in partnership with the Association of Optometrists and is Europe’s fastest growing optical event. It is renowned for its buzzing atmosphere and positive visitor experience, created by the bustling exhibition floor, fashion shows, interactive workshops, world class education programme, learning hubs, design competitions and the central bar.

Visit: www.100percentoptical.com

 

Second Sight

Why Second Sight is supporting the Big Blind Walk 2018

Research into innovative ways to treat blindness is at the heart of all Second Sight does.

Second Sight’s mission is to develop, make and market innovative implantable visual devices to enable blind people to achieve greater independence. Our work bridges the medical science of ophthalmology with engineering.

We are most well known as the developer and manufacturer of the world’s first artificial vision device, Second Sight’s Argus® II, an FDA and CE approved treatment for blindness. Over 250 severely blind individuals around the world are living with the Argus II today.

We hope that soon, the NHS will offer the treatment in the UK too. NHS England announced in December 2016 that it is to assess the quality of life improvements given by the Argus II in 10 British patients with Retinitis Pigmentosa who will receive the implant. They will be followed for a year to evaluate the impact of the device on their independence, mental health and ability to perform everyday tasks before the NHS decides whether or not to join the US, Germany, France and Italy in funding the treatment from government funds.

Second Sight’s research continues with the development of the Orion™ I Visual Cortical Prosthesis – the first ever study to develop a brain implant to restore some vision to individuals who are blind due to causes other than preventable or treatable conditions.

Second Sight believes in the fundamental importance of funding for research that prevents sight loss, treats eye disease, improves the rehabilitation of patients and the restoration of sight and we wish Julian and VisionBridge all the very best of luck on their 1,000 mile journey across the length of Great Britain.

For more information about Argus II, or if you wish to be considered as a patient candidate for the NHS evaluation, please call freephone 0800 520 0925.

Visit: http://secondsight.com

Jeroen Perk

Second Sight patient case study
Read More

Dorothea Kohlhaas

Second Sight patient case study
Read More